Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
etanercept + infliximab + tocilizumab
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
This combination refers to the therapeutic use of three distinct biologic disease-modifying antirheumatic drugs (bDMARDs): **etanercept**, **infliximab**, and **tocilizumab**. Etanercept is a recombinant human TNF receptor-Fc fusion protein, and infliximab is a chimeric monoclonal antibody; both function as tumor necrosis factor (TNF) inhibitors. Tocilizumab is a humanized monoclonal antibody that acts as an interleukin-6 (IL-6) receptor antagonist. These agents are primarily indicated for the treatment of moderate-to-severe rheumatoid arthritis (RA) and other inflammatory conditions. In clinical research, this group of biologics has been evaluated for its efficacy and safety in treating reactive amyloid A (AA) amyloidosis, a severe systemic complication of chronic inflammatory diseases like RA. By suppressing the underlying inflammatory process and reducing serum amyloid A (SAA) levels, these therapies aim to improve survival and preserve renal function in affected patients.
- Brand names
- RoActemra
- Other names
- anti-TNF and anti-IL-6 biologic agents
02
Targets
IL-6R (Interleukin-6 receptor subunit alpha)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on etanercept + infliximab + tocilizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on etanercept + infliximab + tocilizumab.